CN118593463A - 乙酰亮氨酸或其药学上可接受的盐在改善认知功能中的应用 - Google Patents
乙酰亮氨酸或其药学上可接受的盐在改善认知功能中的应用 Download PDFInfo
- Publication number
- CN118593463A CN118593463A CN202410876111.2A CN202410876111A CN118593463A CN 118593463 A CN118593463 A CN 118593463A CN 202410876111 A CN202410876111 A CN 202410876111A CN 118593463 A CN118593463 A CN 118593463A
- Authority
- CN
- China
- Prior art keywords
- acetylleucine
- subject
- pharmaceutically acceptable
- acceptable salt
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1606834.8 | 2016-04-19 | ||
| GB201606834 | 2016-04-19 | ||
| CN201780029480.6A CN109069463B (zh) | 2016-04-19 | 2017-04-19 | 用于改善运动能力和认知功能的乙酰亮氨酸或其药学上可接受的盐 |
| PCT/GB2017/051090 WO2017182802A1 (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780029480.6A Division CN109069463B (zh) | 2016-04-19 | 2017-04-19 | 用于改善运动能力和认知功能的乙酰亮氨酸或其药学上可接受的盐 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118593463A true CN118593463A (zh) | 2024-09-06 |
Family
ID=58633040
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410876111.2A Pending CN118593463A (zh) | 2016-04-19 | 2017-04-19 | 乙酰亮氨酸或其药学上可接受的盐在改善认知功能中的应用 |
| CN201780029480.6A Active CN109069463B (zh) | 2016-04-19 | 2017-04-19 | 用于改善运动能力和认知功能的乙酰亮氨酸或其药学上可接受的盐 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780029480.6A Active CN109069463B (zh) | 2016-04-19 | 2017-04-19 | 用于改善运动能力和认知功能的乙酰亮氨酸或其药学上可接受的盐 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US10905670B2 (https=) |
| EP (2) | EP3445351B1 (https=) |
| JP (3) | JP7387264B2 (https=) |
| KR (4) | KR102632670B1 (https=) |
| CN (2) | CN118593463A (https=) |
| AU (2) | AU2017252507B2 (https=) |
| BR (1) | BR112018071547A2 (https=) |
| CA (1) | CA3021155A1 (https=) |
| DK (1) | DK3445351T3 (https=) |
| ES (1) | ES2994242T3 (https=) |
| FI (1) | FI3445351T3 (https=) |
| HR (1) | HRP20241552T1 (https=) |
| HU (1) | HUE069219T2 (https=) |
| IL (3) | IL262379B (https=) |
| LT (1) | LT3445351T (https=) |
| MD (1) | MD3445351T2 (https=) |
| MX (2) | MX388461B (https=) |
| PL (1) | PL3445351T3 (https=) |
| PT (1) | PT3445351T (https=) |
| RS (1) | RS66142B1 (https=) |
| RU (1) | RU2745912C2 (https=) |
| SG (2) | SG11201809031XA (https=) |
| SI (1) | SI3445351T1 (https=) |
| SM (1) | SMT202400459T1 (https=) |
| WO (1) | WO2017182802A1 (https=) |
| ZA (1) | ZA201806849B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2994242T3 (en) * | 2016-04-19 | 2025-02-05 | Intrabio Ltd | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility |
| WO2018029658A1 (en) | 2016-08-11 | 2018-02-15 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| EP3886986A1 (en) | 2018-12-06 | 2021-10-06 | IntraBio Ltd | Deuterated analogs of acetyl-leucine |
| SMT202400334T1 (it) * | 2019-03-02 | 2024-09-16 | Intrabio Ltd | (n-)acetil-l-leucina per il trattamento di lesioni cerebrali traumatiche |
| US20250099355A1 (en) * | 2023-07-18 | 2025-03-27 | Sytheon Ltd | Amino acid based salts, compositions and methods for treating skin and improving skin rejuvenation and longevity |
| US12403111B2 (en) | 2024-02-02 | 2025-09-02 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| FR2883180B1 (fr) * | 2005-03-18 | 2007-05-25 | Pierre Fabre Medicament Sa | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| US20080097606A1 (en) * | 2006-10-19 | 2008-04-24 | Cragg Andrew H | Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis |
| WO2008134844A1 (en) * | 2007-05-08 | 2008-11-13 | Multi Formulations Ltd. | Branched-chain amino acid composition for improving skeletal muscle protein metabolism |
| WO2011025518A1 (en) * | 2009-08-27 | 2011-03-03 | Albert Einstein College Of Medicine Of Yeshiva University | Cognitive function training to improve motor ability |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| WO2012060844A1 (en) * | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| ES2994242T3 (en) * | 2016-04-19 | 2025-02-05 | Intrabio Ltd | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility |
| US12458614B2 (en) * | 2017-10-18 | 2025-11-04 | Intrabio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
-
2017
- 2017-04-19 ES ES17719692T patent/ES2994242T3/es active Active
- 2017-04-19 SG SG11201809031XA patent/SG11201809031XA/en unknown
- 2017-04-19 RU RU2018140131A patent/RU2745912C2/ru active
- 2017-04-19 MX MX2018012739A patent/MX388461B/es unknown
- 2017-04-19 CA CA3021155A patent/CA3021155A1/en active Pending
- 2017-04-19 WO PCT/GB2017/051090 patent/WO2017182802A1/en not_active Ceased
- 2017-04-19 PT PT177196920T patent/PT3445351T/pt unknown
- 2017-04-19 KR KR1020227021015A patent/KR102632670B1/ko active Active
- 2017-04-19 LT LTEPPCT/GB2017/051090T patent/LT3445351T/lt unknown
- 2017-04-19 BR BR112018071547-6A patent/BR112018071547A2/pt not_active Application Discontinuation
- 2017-04-19 EP EP17719692.0A patent/EP3445351B1/en active Active
- 2017-04-19 CN CN202410876111.2A patent/CN118593463A/zh active Pending
- 2017-04-19 KR KR1020227008412A patent/KR102413754B1/ko active Active
- 2017-04-19 RS RS20241222A patent/RS66142B1/sr unknown
- 2017-04-19 SM SM20240459T patent/SMT202400459T1/it unknown
- 2017-04-19 PL PL17719692.0T patent/PL3445351T3/pl unknown
- 2017-04-19 US US16/093,780 patent/US10905670B2/en active Active
- 2017-04-19 KR KR1020247003393A patent/KR102791288B1/ko active Active
- 2017-04-19 SG SG10202106190RA patent/SG10202106190RA/en unknown
- 2017-04-19 FI FIEP17719692.0T patent/FI3445351T3/fi active
- 2017-04-19 IL IL262379A patent/IL262379B/en unknown
- 2017-04-19 MD MDE20190248T patent/MD3445351T2/ro unknown
- 2017-04-19 IL IL310508A patent/IL310508A/en unknown
- 2017-04-19 EP EP24205813.9A patent/EP4501406A3/en active Pending
- 2017-04-19 HR HRP20241552TT patent/HRP20241552T1/hr unknown
- 2017-04-19 HU HUE17719692A patent/HUE069219T2/hu unknown
- 2017-04-19 CN CN201780029480.6A patent/CN109069463B/zh active Active
- 2017-04-19 IL IL293266A patent/IL293266B2/en unknown
- 2017-04-19 SI SI201731566T patent/SI3445351T1/sl unknown
- 2017-04-19 KR KR1020187032983A patent/KR20180134398A/ko not_active Ceased
- 2017-04-19 JP JP2018555644A patent/JP7387264B2/ja active Active
- 2017-04-19 AU AU2017252507A patent/AU2017252507B2/en active Active
- 2017-04-19 DK DK17719692.0T patent/DK3445351T3/da active
-
2018
- 2018-10-15 ZA ZA2018/06849A patent/ZA201806849B/en unknown
- 2018-10-18 MX MX2021014844A patent/MX2021014844A/es unknown
-
2020
- 2020-12-22 US US17/247,757 patent/US11998518B2/en active Active
-
2021
- 2021-11-12 JP JP2021185130A patent/JP7506046B2/ja active Active
-
2022
- 2022-10-17 AU AU2022256077A patent/AU2022256077A1/en not_active Abandoned
-
2023
- 2023-07-10 US US18/349,221 patent/US12329733B2/en active Active
-
2024
- 2024-06-13 JP JP2024096260A patent/JP2024123087A/ja active Pending
-
2025
- 2025-05-13 US US19/206,473 patent/US20250332133A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109069463B (zh) | 用于改善运动能力和认知功能的乙酰亮氨酸或其药学上可接受的盐 | |
| US20200338034A1 (en) | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders | |
| RU2837641C2 (ru) | Ацетиллейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции | |
| HK40114671A (en) | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function | |
| Chakravorty | Treatment of blepharospasm with levodopa | |
| BR122024012307A2 (pt) | Uso de acetil-leucina ou um sal farmaceuticamente aceitável desta | |
| HK1262576B (en) | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility | |
| HK1262576A1 (en) | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility | |
| NZ787419A (en) | Acetyl-Leucine or a Pharmaceutically Acceptable Salt Thereof for Improved Mobility and Cognitive | |
| WO2025163129A1 (en) | Acetyl-leucine for treating parkinson´s disease | |
| AU2025202077A1 (en) | Therapeutic agents for neurodegenerative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |